PharmGKB summary: ivacaftor pathway, pharmacokinetics/pharmacodynamics

Pharmacogenet Genomics. 2017 Jan;27(1):39-42. doi: 10.1097/FPC.0000000000000246.

Authors

Alison E Fohner¹, Ellen M McDonagh, John P Clancy, Michelle Whirl Carrillo, Russ B Altman, Teri E Klein

Affiliation

¹ Departments of aGenetics bBioengineering, Stanford University, Stanford, California cDepartment of Pediatrics, Cincinnati Children's Hospital Medical Center and University of Cincinnati, Cincinnati, Ohio, USA dGenomics England, Queen Mary University of London, London, UK.

No abstract available

Publication types

Research Support, N.I.H., Extramural

MeSH terms

Aminophenols / pharmacokinetics
Aminophenols / therapeutic use*
Cystic Fibrosis / drug therapy*
Cystic Fibrosis / genetics
Cystic Fibrosis / pathology
Cystic Fibrosis Transmembrane Conductance Regulator / agonists
Cystic Fibrosis Transmembrane Conductance Regulator / genetics*
Humans
Quinolones / pharmacokinetics
Quinolones / therapeutic use*

Substances

Aminophenols
CFTR protein, human
Quinolones
Cystic Fibrosis Transmembrane Conductance Regulator
ivacaftor

Grants and funding

R24 GM061374/GM/NIGMS NIH HHS/United States